Investigating Alzheimer's disease through a clinical network
Official title: Wake Forest NeuroNext Clinical Site (WAKENN)
Funded at Wake Forest University Health Sciences · NIH-10929423 · Data updated 2026-11-12
This study is looking for ways to better understand and treat Alzheimer's disease by involving a diverse group of participants, so if you or someone you know is affected by Alzheimer's, your experience could help improve future treatments.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Wake Forest University Health Sciences NIH-funded |
| Lab location | 1 site (Winston-Salem, United States) |
| Project start | September 15, 2023 |
| Project end | August 31, 2028 |
| Funding year | 2024 |
| Award (this year) | $409,423 |
| NIH project number | 5U24NS107197-07 |
| Project ID | NIH-10929423 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for participation include individuals aged 21 and older who are diagnosed with Alzheimer's disease or related dementias.
✕Less likely to help
Patients with early-stage Alzheimer's disease or those not meeting the specific criteria for the studies may not receive direct benefits from this research.
What this research studies
This research focuses on enhancing the understanding and treatment of Alzheimer's disease by leveraging the NeuroNEXT clinical network. The Wake Forest NeuroNext Clinical Site (WAKENN) has been actively enrolling participants in various studies aimed at improving clinical trial methodologies and patient outcomes. The approach emphasizes diversity in participant recruitment, ensuring representation from underrepresented populations. By collaborating with a large health system, the research aims to expand access to innovative treatments and foster multidisciplinary collaboration among investigators.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options and better management strategies for patients with Alzheimer's disease.
How similar studies have gone: Previous research within the NeuroNEXT network has shown success in enrolling diverse populations and advancing clinical trials for Alzheimer's disease.
Where this research is happening
-
Wake Forest University Health Sciences
Winston-Salem, United States Active
Researchers
- Principal investigator: Ezzeddine, Mustapha Ahmad — Wake Forest University Health Sciences
- Study coordinator: Ezzeddine, Mustapha Ahmad
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.